The newest tenant at the Ion is a West Texas-based oilfield equipment provider. Photo courtesy of the Ion

The Ion's latest tenant is a Texas oilfield equipment provider that's recently seen an uptick in business amid the energy transition.

SCS Technologies, based in Big Spring, Texas, has opened a new office in the Ion, a 266,000-square-foot innovation hub in Midtown, to focus on strategy and innovation. SCS provides CO2 capture measurement and methane vapor recovery equipment for the energy, industrial, and environmental sectors.

“Embracing Houston's pivotal role in the energy transition, the Ion has swiftly become the epicenter of innovative collaborations. For SCS Technologies, this marks an exciting opportunity to align our capabilities and technology with a diverse consortium of organizations working toward ambitious carbon-neutral goals,” says Cody Johnson, CEO of SCS Technologies, in a news release. “Looking ahead, we are invigorated by the boundless possibilities at the Ion, envisioning groundbreaking solutions and technologies that will unfold there.”

The Ion has seen a flurry of activity when it comes to energy tenants. In March, United Kingdom-based Carbon Clean, opened its US headquarters in the Ion as it expands nationally. In April, the Ion named several other new tenants, which included industrial software company Cognite, robotics tech provider Nauticus, and more. These companies join Chevron, which officially opened its new outpost in 2022 after being announced as a founding partner in 2020. ExxonMobil is also a founding partner.

SCS also announced a new executive on its team. On July 20, SCS announced René Vandersalm as COO. Johnson says in a July 20 statement that the appointment comes at a time when "energy and industrial sectors are undergoing a considerable transformation of their processes and infrastructure to align with carbon-neutral goals."

Vandersalm previously worked for over 20 years at Thermon Manufacturing leading the company's heating solutions. In his new role, he says he will work within SCS "to design and produce the innovative compression and measurement systems our customers need to achieve emissions goals."

“It’s an exciting time as energy and industrial companies strive towards sustainable operations, all while delivering the energy and products that customers worldwide rely on,” Vandersalm continues in the release. “I am both excited and honored to collaborate with the talented and motivated SCS Technologies team as we make a significant impact in this industry-wide transition.”

SCS is partnered with New Orleans-based Black Bay Energy Capital, an energy-focused private equity fund.

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

Houston energy hub opens new fundraising cohort to fuel startups

Apply Now

EnergyTech Cypher has opened applications for its second Liftoff fundraising program.

Applications close May 20 for the 10-week virtual fundraising sprint. The program is geared toward energy and climatech founders preparing to raise their first institutional round. It will cover fundraising requisites, like pitch materials, term sheet negotiation and round closing, according to a release from EnergyTech Cypher.

The program kicks off June 1 and runs every Monday from 1-3 p.m. CST. It will conclude with an in-person capstone simulation in Houston on August 3, where founders will work to close a mock round.

Jason Ethier, EnergyTech Cypher founder and CEO, will lead the program with Payal Patel, an EnergyTech fellow and entrepreneur in residence.

The program is available through Cephyron, EnergyTech Cypher's new investor relationship management platform, built specifically for energy and climatech founders. Users must have a Cephyron Boost membership to participate in the Liftoff program.

The Cephyron IRM app recently went live and is available to founders at any point in their fundraising process, according to the news release. The platform aggregates investor data, tracks market signals and delivers curated weekly recommendations.

EnergyTech Cypher launched Liftoff last year. The inaugural cohort included 19 startups, including Houston-based AtmoSpark Technologies, The Woodlands-based Resollant and others. Each participant closed at least one fundraising deal, according to EnergyTech Cypher.

EnergyTech Cypher rebranded from EnergyTech Nexus earlier this year. It also launched its CoPilot accelerator in 2025. The inaugural group presented its first showcase during CERAWeek last month.

EnergyTech Cypher's annual Pilotathon Pilot Pitch and Showcase applications also opened this month. Find more information here.

---

This article originally appeared on EnergyCaptialHTX.com.